Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
BERWYN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today an interview with CEO Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The interview will air Sunday, May 3, at 3 p.m. local time on Bloomberg International, available in 100+ million homes across Europe. In the exclusive interview, Dr. Maccecchini provides an overview of the Company’s clinical trial programs and upcoming milestones. To view the interview segment, please visit: https://youtu.be/QxqQE2NgI8A The interview will also air in the US on the Family Channel on May 6 at 6 p.m., the Action Channel on Sunday May 3 at 11 a.m. and is available via on demand stream on American Business TV. “The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Annovis Bio, Inc. (NYSE: ANVS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $36.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Annovis Bio: Searching For Efficacy In Alzheimer's Disease [Seeking Alpha]Seeking Alpha
- UPDATE 1-Annovis' Alzheimer's treatment helps improve cognition in trial [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
ANVS
Earnings
- 8/14/23 - Beat
ANVS
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- ANVS's page on the SEC website